← TDAC
TDAC— Translational Development Acquisition Corp.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| General and administrative costs | $945K+381.0% | $196K | — |
| Loss from operations | -$945K-381.0% | -$196K+59.6% | -$486K |
| Dividends earned on marketable securities held in Trust Account | $7.3M+5729.4% | $125K | — |
| Total other income | $7.3M+5729.4% | $125K | — |
| Net income (loss) | $6.4M+9059.7% | -$71K+85.4% | -$486K |
| Class A | |||
| Weighted average ordinary shares outstanding, basic (in shares) | $4.7M+14.7% | $4.1M | — |
| Basic net income (loss) per ordinary share (in dollars per share) | $0.29+1550.0% | -$0.02 | — |
| Weighted average ordinary shares outstanding, diluted (in shares) | $4.7M+0.0% | $4.7M | — |
| Diluted net income (loss) per ordinary share (in dollars per share) | $0.29+3000.0% | -$0.01 | — |
| Class B | |||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.